- Fund Type: SICAV
- Objective: Growth
- Asset Class: Equity
- Geographic Focus: Spain
1955 Inversiones SICAV SA
+ Add to WatchlistS0009:SM
5.01 EUR 0.000.00%As of 10:00:50 ET on 05/23/2013.
Snapshot for 1955 Inversiones SICAV SA (S0009)
| Year To Date: | +9.35% | 3-Month: | +7.53% | 3-Year: | +4.89% | 52-Week Range: | 3.82 - 5.04 |
|---|---|---|---|---|---|---|---|
| 1-Month: | +5.56% | 1-Year: | +27.93% | 5-Year: | +1.72% | Beta vs IBEX: | 0.76 |
Fund Profile & Information for S0009
1955 Inversiones SICAV SA is an open-end investment company incorporated in Spain. The investment company's objective is capital growth. It primarily invests in equity securities.
| Inception Date: | 12-08-2006 | Telephone: | 34-91-436-5600 |
|---|---|---|---|
| Managers: | - | ||
| Web Site: | www.privatebanking.fortis.es | ||
Fundamentals for S0009
| NAV | (on 2013-05-23) 5.01 |
|---|---|
| Assets (M) | (on 2013-04-04) 3.58 |
| Fund Leveraged | N |
| Minimum Investment | - |
| Minimum Subsequent Investment | - |
Dividends for S0009
No dividends reported
Fees & Expenses for S0009
| Front Load | - |
|---|---|
| Back Load | - |
| Current Mgmt Fee | 0.80 |
| Redemption Fee | - |
| 12b1 Fee | - |
| Expense Ratio | - |
Top Fund Holdings for S0009
Filing Date: 05/31/2012| Name | Position | Value | % of Total |
|---|---|---|---|
| CUSIP:VGM2 Ù | 17 | 357,850 | 12.594% |
| IDC IBM Sv Rev US | 4 | 242,392 | 8.531% |
| Intel Corp | 9,038 | 188,934 | 6.649% |
| Banco Bilbao Vizcaya Argentari | 38,854 | 178,806 | 6.293% |
| International Business Machine | 1,107 | 172,753 | 6.080% |
| Banco Santander SA | 39,790 | 170,898 | 6.015% |
| Microsoft Corp | 7,233 | 170,804 | 6.011% |
| Coca-Cola Co/The | 5,326 | 160,995 | 5.666% |
| CUSIP:GXM2 Ù | 1 | 155,975 | 5.489% |
| Vodafone Group PLC | 59,393 | 128,076 | 4.508% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page